All In Biotech

Drug Trial Radar · NCT05891093

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 766 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

766

Planned (sponsor's estimate)

Start

Jun 1, 2023

Primary completion

May 31, 2028

Study completion May 31, 2031

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer.

Conditions

  • Breast Cancer

Interventions

  • FluzoparibDrug

    Fluzoparib 50mg bid orally for 1 year.

  • AnastrozoleDrug

    1mg, qd orally

  • LetrozoleDrug

    2.5mg, qd orally

  • ExemestaneDrug

    25mg, qd orally

  • TamoxifenDrug

    10mg, bid orally

  • ToremifeneDrug

    60mg, qd orally

  • AbemaciclibDrug

    150mg/100mg/50mg, bid orally for 2 years

  • LHRH agonistDrug

    Leuprorelin acetate, goserelin acetate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. invasive disease free survival (iDFS)Time frame: 5 years

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangdong, Guangzhou, China · Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai First Maternity and Infant Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.